10-QPeriod: Q2 FY2026

DANAHER CORP /DE/ Quarterly Report for Q2 Ended Jun 26, 2026

Filed July 21, 2026For Securities:DHR

Summary

Danaher Corporation reported solid performance for the first half of 2026, with overall revenues and core sales showing positive growth compared to the prior year. The acquisition of Masimo for approximately $9.8 billion in June 2026 significantly impacted the Diagnostics segment and overall financial figures, contributing to a substantial increase in investing activities. The company saw revenue growth driven by its Life Sciences and Biotechnology segments, while the Diagnostics segment experienced mixed results, impacted by lower respiratory testing demand but boosted by the Masimo acquisition and growth in clinical diagnostics. Geographically, high-growth markets continue to be a strong contributor, with sales increasing significantly, while developed markets showed more modest growth or slight declines. Despite increased interest expenses due to higher borrowings to finance the Masimo acquisition, Danaher's liquidity remains strong, supported by substantial operating cash flow and existing cash reserves. The company anticipates continued investment in organic growth and strategic acquisitions, positioning it for future expansion.

Key Highlights

  • 1Overall revenues increased by 5.5% and core sales by 3.0% in the second quarter of 2026, and 4.5% and 2.0% respectively for the first six months.
  • 2The acquisition of Masimo for approximately $9.8 billion was completed on June 10, 2026, significantly bolstering the Diagnostics segment.
  • 3High-growth markets demonstrated robust growth, with sales up 15% and core sales up over 10% in the second quarter, representing approximately 31% of total sales.
  • 4Net earnings for the first six months of 2026 were approximately $1.9 billion, a significant increase from the prior year, largely due to the absence of a substantial impairment charge recorded in H1 2025.
  • 5Operating profit margins improved significantly across all segments, with notable increases in Life Sciences and Biotechnology, partly driven by the resolution of prior year impairment charges.
  • 6Cash flow from operating activities increased by 8% to $2.9 billion for the first six months of 2026.
  • 7The company declared a regular quarterly dividend of $0.40 per share, payable in July 2026.

Frequently Asked Questions

The acquisition of Masimo for approximately $9.8 billion in June 2026 was a significant event. It was financed through cash on hand and debt issuance, leading to an increase in interest expenses. Masimo has been integrated into the Diagnostics segment and is expected to provide additional sales and earnings opportunities, contributing to overall revenue growth.

Danaher's Biotechnology and Life Sciences segments showed solid core sales growth driven by consumables and equipment demand. The Diagnostics segment saw mixed results, with growth in clinical diagnostics partially offset by a decline in respiratory testing sales, though the Masimo acquisition provided a significant boost to its overall sales.

High-growth markets are a key driver for Danaher, showing strong performance with sales up 15% and core sales up over 10% in the second quarter of 2026. These markets represented approximately 31% of total sales in the quarter, indicating their increasing importance to the company's growth strategy.

The company's liquidity remains strong, supported by substantial cash flow from operations of $2.9 billion in the first six months of 2026 and approximately $4.3 billion in cash and cash equivalents as of June 26, 2026. While debt increased to finance the Masimo acquisition, Danaher has access to commercial paper programs and capital markets and expects its resources to be sufficient for ongoing operations, investments, and strategic acquisitions.